Caricamento...
Chronic lymphocytic leukemia at ASH 2017
At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory settin...
Salvato in:
| Pubblicato in: | Memo |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Vienna
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006235/ https://ncbi.nlm.nih.gov/pubmed/29983825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-018-0414-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|